{
    "clinical_study": {
        "@rank": "21795", 
        "arm_group": [
            {
                "arm_group_label": "EVP unflavoured", 
                "arm_group_type": "Experimental", 
                "description": "Unflavoured e-vapour product"
            }, 
            {
                "arm_group_label": "EVP flavoured", 
                "arm_group_type": "Experimental", 
                "description": "Flavoured e-vapour product"
            }, 
            {
                "arm_group_label": "Nicotine inhalator", 
                "arm_group_type": "Experimental", 
                "description": "Nicotine inhalator 15mg"
            }, 
            {
                "arm_group_label": "Conventional Cigarette", 
                "arm_group_type": "Active Comparator", 
                "description": "Conventional cigarette"
            }
        ], 
        "brief_summary": {
            "textblock": "Electronic Vapour Products (EVPs) are a relatively new class of consumer products that are\n      otherwise known as electronic cigarettes. These may look like conventional cigarettes but do\n      not contain tobacco.\n\n      The 'vapour' produced by such devices typically consists of humectants (propylene glycol or\n      glycerol), nicotine, water, and flavours.\n\n      This trial is to evaluate the pharmacokinetic profile of an EVP."
        }, 
        "brief_title": "A Bioavailability Study of Nicotine Delivered by an Electronic Vapour Product", 
        "condition": "Healthy Volunteers", 
        "detailed_description": {
            "textblock": "The principal part of this study evaluates the nicotine pharmacokinetic profile of\n      conventional cigarettes, a nicotine inhalator, an unflavoured EVP and a flavoured EVP.\n\n      A second part investigates the nicotine delivery of an EVP with four different nicotine\n      doses."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  BMI of 18-35kg/m2\n\n          -  Subjects must be established smokers\n\n          -  Subjects must have smoked five to 30 cigarettes per day for at least one year\n\n        Exclusion Criteria:\n\n          -  Subjects who have used nicotine replacement therapy within 14 days of the screening\n\n          -  Subjects who have donated blood within 12 months preceding study\n\n          -  Subjects with relevant illness history\n\n          -  Subjects positive for hepatitis or HIV\n\n          -  Subjects with history of drug or alcohol abuse\n\n          -  Subjects with lung function test or vital signs considered unsuitable\n\n          -  Subjects who are trying to stop smoking"
            }, 
            "gender": "Male", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "65 Years", 
            "minimum_age": "21 Years"
        }, 
        "enrollment": {
            "#text": "24", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "January 6, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02032212", 
            "org_study_id": "ITG EVP G1 S1"
        }, 
        "intervention": [
            {
                "arm_group_label": "EVP unflavoured", 
                "intervention_name": "EVP unflavoured", 
                "intervention_type": "Other"
            }, 
            {
                "arm_group_label": "EVP flavoured", 
                "intervention_name": "EVP flavoured", 
                "intervention_type": "Other"
            }, 
            {
                "arm_group_label": "Nicotine inhalator", 
                "intervention_name": "Nicotine inhalator 15mg", 
                "intervention_type": "Other"
            }, 
            {
                "arm_group_label": "Conventional Cigarette", 
                "intervention_name": "Conventional cigarette", 
                "intervention_type": "Other"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Nicotine", 
                "Nicotine polacrilex"
            ]
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "May 9, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Merthyr Tydfil", 
                    "country": "United Kingdom", 
                    "state": "Wales", 
                    "zip": "CF48 4DR"
                }, 
                "name": "Simbec Research"
            }
        }, 
        "location_countries": {
            "country": "United Kingdom"
        }, 
        "number_of_arms": "4", 
        "official_title": "A Randomised, Crossover, Relative Bioavailability Study of Nicotine Delivered by an Electronic Vapour Product, a Nicotine Inhalator and a Conventional Cigarette", 
        "overall_official": {
            "affiliation": "Simbec Research", 
            "last_name": "Girish Sharma, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United Kingdom: Medicines and Healthcare Products Regulatory Agency", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "May 2014", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "measure": "Nicotine plasma concentration", 
                "safety_issue": "No", 
                "time_frame": "Up to 5 days"
            }, 
            {
                "measure": "Area under the concentration-time curve for plasma nicotine", 
                "safety_issue": "No", 
                "time_frame": "Up to 5 days"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02032212"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Vital signs", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 5 days"
            }, 
            {
                "measure": "Craving and withdrawal symptoms", 
                "safety_issue": "No", 
                "time_frame": "Up to 5 days"
            }
        ], 
        "source": "Imperial Tobacco Group PLC", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Imperial Tobacco Group PLC", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "December 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}